ArticleAnnals of gastroenterological surgery2023

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma.

Yukinori Kurokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.